A Phase 1 Single Ascending Dose Trial to Explore Safety, Tolerability, Pharmacokinetics and Target Engagement of VRDN-002 in Healthy Volunteers
Latest Information Update: 12 Jul 2023
At a glance
- Drugs VRDN 002 (Primary) ; VRDN 002 (Primary)
- Indications Graves ophthalmopathy
- Focus Adverse reactions; First in man
- 10 Jul 2023 Status changed from recruiting to active, no longer recruiting according to a Viridian Therapeutics media release.
- 09 May 2023 According to Viridian Therapeutics media release, data from this study were highlighted in an oral presentation at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO 2023).
- 20 Apr 2023 According to Viridian Therapeutics media release, data from this study will be presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO 2023); Following their presentation at ARVO 2023, the above abstracts will be posted at www.viridiantherapeutics.com/pipeline/scientific-presentations.